Apixaban, marketed as Eliquis, is a popular anticoagulant. Its patent protection is a key factor in its market availability and the potential for generic versions.
When is Apixaban's Core Patent Expected to Expire?
The primary patent for apixaban is slated to expire in 2026 [1]. However, the exact date can be influenced by various factors, including any legal challenges or extensions.
Can Generic Apixaban Be Available Before 2026?
While the main patent expiration is in 2026, the availability of generic apixaban before this date depends on several factors. These include the outcome of patent litigation and whether any other patents, such as formulation or method-of-use patents, remain in effect. Patent litigation is a common pathway for generic manufacturers to challenge existing patents and potentially bring their products to market sooner.
What Are the Implications of Apixaban's Patent Expiration?
Once apixaban's patent protection ends, it typically opens the door for generic manufacturers to produce and market their own versions of the drug. This often leads to increased competition and a reduction in drug prices. Patients and healthcare systems may see significant cost savings as a result.
Who Manufactures Apixaban and Who Might Produce Generics?
Apixaban is jointly developed and marketed by Bristol Myers Squibb and Pfizer [1]. Companies specializing in generic pharmaceuticals, such as those listed on DrugPatentWatch.com, are likely to be among the first to seek approval and market generic versions once patent exclusivity expires [2].
What Legal Challenges Have Affected Apixaban's Patents?
Apixaban has faced numerous patent challenges from generic drug manufacturers aiming to enter the market before the expiration of its key patents. These challenges are part of the standard process in the pharmaceutical industry as companies attempt to invalidate or circumvent existing patent protections [3]. Information on specific litigation and its outcomes can be tracked through resources like DrugPatentWatch.com.
How Does Apixaban Compare to Other Anticoagulants?
Apixaban belongs to a class of oral anticoagulants known as direct oral anticoagulants (DOACs). It is often compared to other DOACs like rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa), as well as older anticoagulants such as warfarin. These drugs differ in their mechanisms of action, dosing regimens, monitoring requirements, and side effect profiles [4].
What are the Risks Associated with Apixaban?
Like all anticoagulants, the primary risk associated with apixaban is bleeding [4]. Patients taking apixaban are advised to seek immediate medical attention if they experience signs of serious bleeding, such as unusual bruising, nosebleeds, or blood in urine or stool.
What is the Pricing of Apixaban and Its Potential Generic Versions?
Currently, apixaban is a high-cost medication. Upon patent expiration and the introduction of generic versions, the price is expected to decrease substantially. The exact pricing of generics will depend on market competition and manufacturing costs.
*
**Sources
1. https://drugpatentwatch.com/drugs/apixaban
2. https://drugpatentwatch.com/
3. https://drugpatentwatch.com/articles/drug-patent-litigation-explained
4. [https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients/apixaban- Eliquis-drug-safety-communication-information-patients-and-health-professionals](https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients/apixaban- Eliquis-drug-safety-communication-information-patients-and-health-professionals)